The acute effect of Conclusion Acute application of pilocarpine 2% drops increased POBF to a significant extent in untreated ocular hypertension.
Materials and methods

Consecutive
Ninety minutes after the last application, the measurements were repeated. The same examiner took all measurements. Soth eyes of each subject were tested, the right eye first. Due to obvious difficulties in masking the miotic effect of pilocarpine, the study design was not masked.
The study protocol was accepted by the Wigan and Leigh NHS Trust ethics committee. Informed consent was obtained for each patient following complete explanation of the procedure.
Since there was some evidence of skewness of the data, a non-parametric statistical method in the form of the Wilcoxon signed rank test was employed. Five per cent was considered as the level of significance.
Results
Of 18 patients who entered the trial, 2 had 'poorly reliable data' as suggested by the OSF system computer software. The final analysis was done on 16 patients. Their mean age was 67 years (range 58�79 years). Nine of 16 (58%) were women.
lOP decreased significantly in the pilocarpine-treated eyes at 90 min (p = 0.02; Table 1 ). The change in the contralateral control eyes was statistically not significant.
POSF increased significantly in pilocarpine-treated eyes at 90 min (p = 0.01; Table 2 ). The change in the contralateral control eyes was statistically not significant.
The difference in the change in lOP (comparison between the treated and control eyes) was significant (p = 0.001; Table 3 ). The difference in the change in POBF (comparison between the treated and control eyes) was also significant (p < 0.001; Table 3 ). This suggests that pilocarpine increased POSF significantly.
Discussion
The idea that lOP alone does not account for the development of all glaucomatous optic neuropathy is now commonly accepted. Vascular factors including altered ocular blood flow and optic nerve perfusion appear to be important. It is therefore imperative that antiglaucoma agents are evaluated for their haemodynamic as well as their hypotensive effect.
In our study, the acute application of pilocarpine 2% drops decreased lOP significantly at 90 min. It also produced a significant increase in POSF. As we used the patient's contralateral eye as a control, systemic variables such as heart rate and systemic pressure are not relevant to the conclusion. The increase in POSF observed in our study may be the indirect result of a decrease in lOP, which in turn could lead to an increase in perfusion pressure. However, the current antiglaucoma drugs that reduce lOP do not necessarily increase ocular blood flow.s This is possibly due to reactive vasoconstriction secondary to the fall in lOP, tending to produce the effect in the opposite direction.6
The muscarinic parasympathetic fibres, which are known to be vasodilatory in function, richly supply both the choroidal circulation and ciliary arteries? In rabbits and cats, intra-arterial injection of acetylcholine causes an increase in choroidal blood flow.8 In monkeys, atropine abolishes pilocarpine-induced uveal vasodilatation, suggesting the effect is mediated through vascular muscarinic receptors.9 In this context it is interesting to note that in human volunteers a significant reduction in POSF that is independent of pupillary changes is We gratefully acknowledge Dr Chris Robert, senior lecturer in medical statistics, Manchester University, for his expert advice on statistical matters.
